

4<sup>th</sup> April 2024

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001  <b>BSE – AJANTPHARM 532331</b>	National Stock Exchange of India, Exchange Plaza, 5 <sup>th</sup> Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051  <b>NSE AJANTPHARM EQ</b>	Audit Committee Ajanta Pharma Limited
--	--	--

**Re: Disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Dear Sir/ Madam,

Pursuant to provisions of Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, I hereby declare on behalf of promoters & promoter group of Ajanta Pharma Ltd. that we have not made any encumbrance, directly or indirectly, other than those already disclosed during the financial year ended 31<sup>st</sup> March 2024.

Thanking you,  
Yours faithfully,

---

**YOGESH M. AGRAWAL**

C.C. : The Company Secretary  
Ajanta Pharma Limited  
“Ajanta House”,  
Charkop, Kandivli (West)  
Mumbai – 400 067